Radiation dermatitis (supportive care)
Also known as: Radiotherapy-induced dermatitis, Radiation skin injury, Radiation-induced skin reaction, Radiation-induced skin toxicity
Radiation dermatitis constitutes cutaneous injury within a radiotherapy field, presenting as erythema, pruritus, dry desquamation, moist desquamation, ulceration, and pain. Clinical management is directed by the radiation oncology team, prioritising standardised assessment, approved skin care, wound dressings, and symptom control. Interruption of radiotherapy must never be undertaken independently. While Traditional Chinese Medicine provides a framework for supportive care, the cited evidence includes no human acupuncture trials or clinical data validating the oral formulas for this condition. Data for topical products rely on animal models, computational modelling, or in vitro experiments, which do not establish patient benefit. Furthermore, analysis of digital video content indicates that online information regarding this topic is frequently unreliable. The provided safety guidance reflects standard clinical precaution rather than findings derived from the research abstracts.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Lave the affected area gently according to radiation oncology protocols, pat dry, and avoid mechanical irritation or debridement of desquamating skin.
- •Utilise soft, non-restrictive clothing to minimise friction over the treatment field.
- •Maintain protection from solar radiation and thermal extremes; refrain from applying thermotherapy, cryotherapy, or adhesive products unless clinically approved.
- •Maintain adequate nutritional and fluid intake within medical guidelines, and report involuntary weight loss or difficulty eating promptly.
Cautions & Contraindications
- •Do not needle, cup, scrape or apply moxibustion over irradiated, inflamed, broken or infected skin. This is a precautionary practice restriction; the supplied preclinical topical study does not establish procedural safety.[]
- •Do not extrapolate the animal, cell or computational findings into use of experimental gels, oils, herbal washes or oral formulas during radiotherapy. Obtain oncology approval for all products applied to the treatment field.[,,]
- •Defer elective needling pending oncology clearance in clinically significant neutropenia, thrombocytopenia, active infection or unstable illness; assess anticoagulation individually. These clinical precautions are not evaluated in the supplied evidence and should not be replaced by social-media advice.[]
When to reassess or seek care again
Arrange an initial supportive-care review within 3–7 days, alongside the oncology team's assessment schedule. Record oncology-assessed skin grade, dry versus moist desquamation, affected area, pain and itch scores from 0–10, sleep and intake. Escalate new breakdown or deterioration the same day rather than waiting for review. Reconsider or stop adjunctive treatment if there is no meaningful symptom benefit after 1–2 weeks, intolerance or interference with cancer care.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Frontiers in public health · 2026
- ACS applied materials & interfaces · 2026
- Current computer-aided drug design · 2026
- BMC complementary medicine and therapies · 2025
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
